

REVIEW: TREATMENT OF *HELICOBACTER PYLORI* INFECTION 2022

A. O'Connor

Department of Gastroenterology, Tallaght University Hospital/Trinity College Dublin, Dublin, Ireland

Corresponding Author: Anthony O'Connor MD, e-mail: jpoconno@tcd.ie

Abstract – This review summarizes important studies regarding *Helicobacter pylori* therapy published from March 2021 to March 2022. Some of the major themes that emerge involve studies assessing the efficacy of high dose dual therapy regimens, the huge promise shown by vonoprazan as a component of eradication therapy and the use of personalised therapy. The nature of much of the work conducted over the last year has been dictated somewhat by the demands of the pandemic era, with far more systematic reviews and data syntheses and fewer original data on important factors such as resistance rates. Nonetheless, other studies have also been published which strengthen the importance of bismuth-based therapies, quadruple regimens and the use of novel tetracyclines and fluoroquinolones. A further body of work was undertaken on factors influencing the success and failure of therapies, all of which greatly enabling us to tackle the twin problems of antibiotic resistance and patient adherence to therapy.

Keywords: *H. pylori*, Treatment, Resistance, Compliance, Triple therapy, Bismuth.

INTRODUCTION

Compared to most of the last decade, this year has been a relatively fallow one in terms of the quantity of original research publications on the treatment of *Helicobacter pylori*, most likely reflecting the difficulty in undertaking clinical research in the midst of a global pandemic¹. This was felt most keenly in the field of antibiotic resistance, with the attentions and efforts of many microbiology and infectious diseases departments being required elsewhere. In addition, the number of consensus guidelines was very low with meetings being very difficult to arrange. Two exceptions here were in Korea where a guideline emerged that endorsed standard triple therapy, concomitant therapy and sequential therapy for first line and bismuth-based therapy most strongly for second-line treatment, and in Spain where only quadruple therapies (with or without bismuth) and generally lasting 14 days, are recommended as first-line regimens^{2,3}. That notwithstanding, the quality of research remains high and of an innovative and practical nature.

DUAL AND TRIPLE THERAPY AS A FIRST LINE TREATMENT

Given the longstanding concerns that the rates of eradication from standard triple therapy are falling, a number of data syntheses this year attempted to address this question. A very extensive network meta-analysis of randomised controlled trials (RCTs) concluded that standard triple therapy with proton pump inhibitors (PPIs) was the worst performing regimen but when vonoprazan was used, triple therapy was the only regimen that obtained eradication in



This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/)

more than 90% of cases (92.5%), with levofloxacin-based therapy being the most efficacious in western countries, where vonoprazan has not been trialed (88.5% eradication)⁴. In this study, standard triple therapy had an overall efficacy of 75.7% consisting of 67.8% in western countries and 75.9% in east Asia. This regional variation was also seen in a meta-analysis and systematic review of 121 trials comprising 34,759 participants which looked at eradication rates from RCTs of first line therapies in various global regions, finding 14-day levofloxacin-based sequential therapy as the most efficient overall followed by modified bismuth-containing quadruple therapy for 10 days. Ten-day clarithromycin-based sequential therapy was the most efficacious in Africa, 14-day levofloxacin-based sequential therapy in Asia, and 14-day clarithromycin-based triple therapy in Europe, with North America generating insufficient data for network meta-analysis and in South America, none of the combinations were superior to the reference regimen⁵.

As resistance rates and compliance are thought to be the two greatest obstacles to *H. pylori* eradication, in recent years the relatively simple concept of dual therapy with PPI and amoxicillin has grown in popularity. One study from China assessed eradication rates with a four times daily high dose dual therapy and found eradication rates of 85.8%, comparable with bismuth quadruple therapy, albeit lower rates were noted in smokers and overweight individuals⁶. Three systematic reviews were conducted on this dual therapy. The first showed that dual therapy had an identical eradication rate to mainstream first line therapies (90%) but with significantly fewer side effects, 8.70% vs. 22.38%⁷. Another meta-analysis⁸ also reported 90% eradication for dual therapy, as compared to 85% for standard first line treatments. This data synthesis looked further at second line therapy and found dual therapy in this setting to be equal to standard guideline treatments. Again, an encouraging finding regarding tolerability and safety was observed with 19.6% reporting side effects with dual therapy compared to 36.7% with others but no difference in compliance. A further network meta-analysis, however, compared high-dose dual therapy (HDDT), bismuth-based quadruple therapy (BQT), sequential therapy (ST), concomitant therapy (CT) and hybrid therapy (HT) in the Asian population and again found HDDT to be the most effective regimen with the fewest side effects⁹.

FLUOROQUINOLONES AS SECOND LINE TREATMENT

The use of fluoroquinolones with amoxicillin as salvage therapy in *H. pylori* eradication is a feature of the Maastricht V/Florence Consensus Report¹⁰, although in recent years fluoroquinolone resistance has called this use into some question. A large study from a Taiwanese consortium investigated the efficacies of tetracycline-levofloxacin (TL) quadruple therapy and amoxicillin-levofloxacin (AL) quadruple therapy in the second-line treatment of *H. pylori* infection and had to be terminated after interim analysis due to clear superiority in favour of TL quadruple therapy (95% eradication) compared to AL quadruple therapy (69.6%), both including bismuth¹¹. TL therapy remained quite efficacious even when levofloxacin-resistant strains were present (88.9%). In another trial aiming to increase options in the era of fluoroquinolone resistance, a novel fluoroquinolone antofloxacin was also trialed this year as part of a triple regimen in a group of 196 patients who had previously failed standard triple or BQT and yielded significantly superior eradication (87.6% vs. 68.5%) compared to levofloxacin based triple therapy with similar adverse event rates¹². A similar study looked at antofloxacin and levofloxacin as components of BQT, again with superior eradication rates for the antofloxacin group (93.8%) compared to 86.2% in the levofloxacin group¹³.

BISMUTH

Several studies this year assessed the various places where bismuth may be of use in *H. pylori* treatment. One RCT looked at ranitidine bismuth citrate (RBC) as a pre-treatment before standard triple therapy for *H. pylori* eradication and showed superior eradication in the pre-treatment group (80.9% vs. 67.3%), but was terminated early, due to a global safety concern regarding N-nitrosodimethylamine with ranitidine¹⁴. A more conventional, rando-

mised, open-label trial conducted in Korea compared the efficacy of 10-day BQT with 7-day PPI-clarithromycin containing standard triple therapy (STT) as an empirical first-line therapy with the BQT group achieving a significantly higher eradication rate (74.3% versus 57.1%) albeit with poorer compliance and a higher rate of adverse events¹⁵. Numerous studies over the years have addressed various different antibiotic regimen components as part of bismuth based therapy. One such trial this year randomised patients to 12-day quadruple therapy regimens containing either tetracycline or furazolidone with the tetracycline group doing better at 87.1% eradication versus 83.9% with furazolidone, also with a significantly lower incidence of adverse events¹⁶. A systematic review comparing BQT and CT was conducted and yielded no difference of cure rate between BQT and CT (84.6% vs. 82.9%)¹⁷. A further study looked at modes of delivery of bismuth, which has been proposed as a way to address some concerns regarding the tolerability of bismuth, by comparing bismuth pectin capsules and bismuth pectin granules in the first-line quadruple treatment of *H. pylori*; however, there was no significant difference in eradication rate, symptom improvement rate, overall adverse reaction rate, or patient compliance¹⁸.

SEQUENTIAL/CONCOMITANT/HYBRID/QUADRUPLE THERAPY

Original research on these therapies was sparse this year, however, a number of interesting data syntheses were published. One such systematic review of 24 trials including over 7,000 patients found CT to be superior to ST, particularly in the Asian setting even when only prescribed for 10 days compared to 14 days of ST, albeit with higher rates of adverse events¹⁹. Reverse hybrid therapy is a regimen that is proposed to combine the advantages of both CT and ST, using the same drugs but in reverse sequence, usually PPI plus amoxicillin and 2 other antibiotics for 7 days then PPI with amoxicillin alone for 3-7 days. A meta-analysis of four studies with 1,530 patients found a crude eradication rate of 95.5% with encouraging rates of 89% among clarithromycin resistant strains, 91% with metronidazole resistance and 86% for dual resistant strains²⁰. Apart from these data syntheses, two interesting studies were completed in the Arab world. One such study on ST from Saudi Arabia reported very poor eradication rates of 63.4% for ST and 67.1% for STT, albeit with better cost-effectiveness for ST²¹. Another study in Syria compared doxycycline quadruple therapy with levofloxacin concomitant therapy with respective eradication rates of 76.9% and 82.1%²².

PERSONALISED THERAPY

Personalised therapy guided by antibiotic susceptibility testing and host factors is growing in prominence. A meta-analysis conducted on 16 studies including nearly 5,000 patients found susceptibility-guided therapy to be superior to first-line clarithromycin-based triple therapy when clarithromycin resistance exceeded 20%²³. Regarding host genetic factors a separate meta-analysis of 57 studies from 11 countries looked at the role of host genetics in treatment failure²⁴. The bulk of the data and the most striking findings concerned the CYP2C19 polymorphism. This showed that enhanced vs poor metabolizer phenotypes were associated with a 2.52-fold significantly higher likelihood of eradication failure and a 4.44-fold significantly higher likelihood when treatment adherence and *H. pylori* clarithromycin susceptibility (if relevant) were confirmed. A separate meta-analysis of the same topic with an Asian focus found that CYP2C19 polymorphism only influenced the *H. pylori* eradication rate in China and Japan and that rabeprazole-, esomeprazole- and pantoprazole-based regimens were not affected as much²⁵. An intriguing prospective study examined the possibility that visual gene clip technology could be used to detect clarithromycin resistance and CYP2C19 status from gastric mucosal biopsies to guide the specific components of a 14-day BQT regimen²⁶. Among the 242 patients who received tailored therapy, the *H. pylori* eradication rate was 91%. Other studies, however, demurred from the enthusiasm for susceptibility-based therapy. One group studied 490 *H. pylori*-positive patients retrospectively and found the eradication rate in a group where treatment was tailored based on clarithromycin susceptibility testing to be 87.8% compared to 91.8% in an empirical BQT

group, with the latter experiencing fewer adverse events and lower costs of care²⁷. Another published meta-analysis of 48 studies found 95% of patients with supposedly susceptible strains but only 63.4% of those patients achieved good eradication rates, again suggesting the importance of adherence to therapy²⁸.

THE BARRIERS TO TREATMENT SUCCESS: COMPLIANCE AND RESISTANCE

It is widely accepted that the two greatest challenges in optimising treatments for *H. pylori* are improving patient compliance and overcoming antimicrobial resistance. Regarding compliance, it is of crucial importance that patients are adequately educated and informed on the components of their *H. pylori* eradication treatment which can be complex, with benefits to the patient that may not be immediately apparent. A meta-analysis of Enhanced Patient Education (EPE) programmes found that these led to markedly improved adherence to therapy and eradication rates²⁹. In China, an initiative to use a social media platform to provide patients with education, support and encouragement during their therapy period led to an eradication rate of 90% compared to 77% in controls³⁰. A systematic review was conducted this year where enhanced patient instructions (EPI) used methods such as telephone-based re-education, short-message service, and WeChat³¹. It was noted that compared with patients receiving only regular instructions, patients receiving EPI showed significantly higher *H. pylori* eradication rates (RR = 1.20) and better patient compliance (RR = 1.23), as well as higher patient satisfaction (RR = 1.42). A similar meta-analysis with some overlap of technology-enhanced communication (TEC) strategies also found that such initiatives significantly improved patient compliance (OR 4.52) and eradication rate (OR 1.98)³².

As microbiologists around the world struggled with an unprecedented challenge during the pandemic it is perhaps unsurprising that there were comparatively few studies published on *H. pylori* resistance rates. One significant meta-analysis from a region not previously well studied was conducted on resistance rates in Australia and New Zealand over the last 20 years and showed a more than doubling of clarithromycin resistance, from 7.4% to 16.1%, with stable rates of resistance to metronidazole, fluoroquinolone, amoxicillin and tetracycline in that time frame³³. The individual studies detailing resistance are summarised in Table 1³³⁻⁴⁰. Finally, an interesting meta-analysis reported on the phenomenon of heteroresistance, *i.e.*, the presence of resistant and susceptible *H.*

TABLE 1. HELICOBACTER PYLORI RESISTANCE TO ANTIBIOTICS IN THE STUDIES PUBLISHED DURING THE LAST YEAR WORLDWIDE.

Author	N	Region	AMO %	CLA %	MET %	QUINOLONE %	TET %	RIF %
Schubert ^{33*}	1810	Australia & New Zealand	2.1	16.1	50.5	(ALL) 2.9	0.3	-
Hallur ³⁴	93	India	3.1	34.4	81.2	(LVX) 65.6	-	-
Tian ³⁵	180	China	15.1	25.5	96.4	(LVX) 67.3	-	-
Vanden Bulcke ³⁶	512	Belgium	2.7	13.5	29.7	(LVX) 29.7	0.0	11.4
Ho ^{37*}	2660	USA	2.6	31.5	42.1	(LVX) 37.6	0.9	0.2
Nestegard ³⁸	50	Norway	-	11	38	-	12	-
Azadbakht ³⁹	205	Iran	46.8	70.7	33.2	(LVX) 36.1	41	-
Li ⁴⁰	54	China	18.5	50.0	77.8	(LVX) 33.3	13	-

*Meta-analysis AMO = Amoxicillin, CLA = Clarithromycin, MET = Metronidazole, TET = Tetracycline, RIF = Rifabutin, LVX = Levofloxacin.

pylori populations in the same sample and/or a difference in the susceptibility patterns between biopsy samples⁴¹. The analysis of 22 studies that had investigated 3,852 *H. pylori* positive patients found 6.8% heteroresistance to clarithromycin and 13.8% to metronidazole.

ACID INHIBITION – PROTON PUMP INHIBITORS AND POTASSIUM COMPETITIVE ACID BLOCKERS

Vonoprazan, the first potassium competitive blocker (P-CAB) has again been the subject of much interest in the field of *H. pylori* eradication with consistently strong results in recent years. A study from Thailand showed eradication rates of 96.7% for 7-day vonoprazan triple therapy compared to 88.5% for a 14-day course of STT⁴². However, the results of vonoprazan were not quite as impressive when used as part of a dual therapy, with rates of 66.7% for 7 days of treatment and 89.2% for 10 days⁴³. A second P-CAB, tegoprazan, underwent a pharmacokinetic and pharmacodynamic study when co-administered with amoxicillin/clarithromycin in healthy subjects and illustrated a more favourable gastric pH profile for the agent compared to pantoprazole⁴⁴. Continuing on the theme of PPIs, a further meta-analysis concluded that for the triple therapy regimen of PPI- clarithromycin-metronidazole, and the common practice of using PPIs prior to eradication therapy were associated with higher rates of eradication, albeit not for other regimens⁴⁵.

OTHER ANTIBIOTIC TRIALS

Data emerged on several other antibiotics used as part of *H. pylori* eradication treatments this year. Regarding furazolidone, in a high clarithromycin resistance region, furazolidone-based BQT achieved 92% eradication compared to 88% for clarithromycin and was seen to have superior cost-effectiveness and acceptable safety⁴⁶. Doxycycline is another agent considered to be capable of overcoming resistance challenges. A meta-analysis was therefore conducted on doxycycline and minocycline as part of eradication treatment, looking at 23 studies and over 5,000 patients. It was noted that when these synthetic tetracyclines were used as part of triple therapy, the eradication rates were less than 75% compared to 95% in quadruple therapies⁴⁷. Yet another systematic review examined rifabutin as part of both first-line and rescue therapies; it showed a severe lack of studies on the agent as part of first line therapy compared with conventional treatment controls, with just one study on first line therapy. For all uses, it was noted that treatment was more likely to be successful in Asian versus non-Asian populations (81.0% vs. 72.4%) with an overall rate of 24.8% for adverse events⁴⁸.

PROBIOTICS AND OTHER ADJUNCTS TO THERAPY

For many years now probiotics have been studied as a means of improving *H. pylori* eradication rates. The proposed mechanisms for this include a direct anti-*H. pylori* effect and also the possibility that co-prescription of probiotics while people are on therapy will reduce the side effects associated with therapy and thereby improve adherence. Lactobacilli have been the most frequently studied agents and several studies emerged from Asia this year to shed more light on this topic. One study looked at the role of non-viable *Lactobacillus reuteri* DSM17648 combined with 14-day STT on *H. pylori* eradication, and although eradication rates were not improved (81%), supplementation helped to build up a beneficial microbial profile and reduced the frequencies of abdominal distention, diarrhoea, and the Gastrointestinal Symptom Rating Score, possibly via an effect on any concurrent irritable bowel syndrome⁴⁹. Other studies looked at Lactobacilli in combination with other adjuncts. A Taiwanese paper looked at the role of *Lactobacillus rhamnosus* on the bacterial load and found that the agents significantly decreased the number of organisms and modified the gut microbiota, although no eradications were observed in the RCT of 40-patients⁵⁰. In Iran, a double-blind RCT was conducted comparing treatment with *Lactobacillus reuteri* and

Saccharomyces boulardii and found both to be superior to the non-probiotic arm (92.3% and 94.2% respectively, compared to 86.5% for the controls), but with only the *S. boulardii* group reaching statistical significance both in terms of eradication and in reducing side effects⁵¹.

A number of probiotic studies were also conducted in Europe. In Turkey, a study of 400 patients showed significantly increased efficacy when bovine lactoferrin was added to both STT and ST, with a 10-day ST plus lactoferrin reaching the highest eradication rate of 94.5%⁵². A further probiotic study from a Greek group looked at the addition of a four strain containing probiotic (*Lactobacillus acidophilus*, *Lactiplantibacillus plantarum*, *Bifidobacterium lactis*, and *S. boulardii*) along with a 10-day concomitant non-bismuth quadruple *H. pylori* eradication regimen. The results of this trial were encouraging with an increase in eradication rate from 86.8% to 92% noted in the probiotic group, as well as a markedly reduced incidence of side effects (17% vs. 51%)⁵³.

In a South American cohort, the addition of *S. boulardii* CNCM-I 745 to the conventional antibiotic eradication therapy for *H. pylori* reduced the number of antimicrobial resistance genes (ARGs) in the faeces compared to the standard of care⁵⁴.

As well as probiotics, a few other treatment adjuncts were studied this year. An Egyptian study found that vitamin D supplementation to a 14day STT was associated with increased eradication rates ranging from 61% to 80%⁵⁵. The effect of periodontal treatments in eradicating *H. pylori* has long been discussed and this year a systematic review and meta-analysis conducted on the topic found that the addition of a periodontal treatment resulted in improvement in gastric *H. pylori* eradication rates with an OR of 4.11 and non-recurrence rates with an OR of 5.36⁵⁶.

EFFECT OF H. PYLORI ERADICATION ON THE MICROBIOTA

Further data have accrued this year on the effect of *H. pylori* eradication on the microbiota. One study showed that after eradication the gastric microbiota was significantly disrupted in young adults, and this could not be restored in a short time⁵⁷. When probiotics were used to supplement eradication treatment, the microbial diversity was closer to that of *H. pylori*-negative patients compared to the standard quadruple therapy group. *H. pylori* eradication therapy alters gut microbiota, provoking gastrointestinal symptoms that could be improved by probiotics. A study from Germany assessed the effect of fermented milk, containing yogurt and *Lactocaseibacillus* (*L. rhamnosus* and *L. paracasei*), on *H. pylori* positive patients and found that, following *H. pylori* treatment, there was a significantly faster recovery of the microbiota composition (beta-diversity) and short chain fatty acid production as well as a limited increase in potentially pathogenic bacteria⁵⁸. A meta-analysis of studies looking at the effect of eradication treatment on the gastric microbiota found that successful *H. pylori* eradication could reverse the gastric microbiota dysbiosis and show beneficial effects, potentially providing new insight for exploring the role of *H. pylori* and the whole gastric microbiota in gastric carcinogenesis⁵⁹.

FACTORS INFLUENCING SUCCESS OF TREATMENT

Several other interesting articles emerged this year looking at tangential factors that may influence treatment success or failure. One comprehensive meta-analysis of the effect of *H. pylori* eradication on diabetes mellitus examined 36 studies and found that, while the risk of treatment failure was higher in diabetic patients (OR = 2.59), successful eradication improved glycaemic control⁶⁰. Another meta-analysis looked at the role of smoking and found that, overall in 39 studies, smoking increased the failure rate of *H. pylori* eradication treatment (OR = 1.70) rising to an OR of 2.59 when the number of cigarettes per day was increased by more than five⁶¹. A further meta-analysis looking at the phenomenon of recurrence and recrudescence found an annual rate of 4%, and a stable trend with the time elapsed after eradication⁶². A systematic review and meta-analysis of 12 studies found the eradication rate of whole-family treatment was higher (OR=2.93) and recurrence rate was lower (OR=0.3)⁶³.

Physician factors are also at play. A study of Chinese physicians found 26.5% of respondents indicating that their hospitals had dedicated clinics for managing *H. pylori* infection, with 91.0% of respondents having routinely recommended a reexamination 1 to 2 months after eradication therapy, and 95.1% were advised to stop PPI treatment at least 2 weeks before re-examination. The authors concluded that the physician's skills and knowledge concerning the diagnosis and treatment of *H. pylori* infection could be improved⁶⁴.

CONCLUSIONS

Many studies pertaining to *H. pylori* eradication treatment were found in the published literature over the last 12 months, across a diversity of topics, although several broad themes emerged. Given the extenuating circumstances of the last 2 and a half years, much of the literature was in the form of data synthesis. This particular modality, in fact, may be considered to be at a crossroads in the *H. pylori* treatment field, as criticism emerged this year that the information coming from them is undermined by problems such as the poor quality of the clinical trials using non-optimised regimens and incomparable comparisons related to marked geographic and ethnic genotypic and phenotypic heterogeneity⁶⁵.

The concept of high dose dual therapy with PPI, if not vonoprazan, and amoxicillin has certainly produced robust data this year and is likely to grow in popularity. Regarding fluoroquinolones, the novel agent antofloxacin may offer some promise as a means of dealing with rising levofloxacin resistance. Personalised therapy continues to offer an attractive emergent means of prescribing effective therapy, although it remains to be seen what the exact advantage will be in terms of eradication therapy over existing empirical regimens. As ever, the biggest barriers to treatment success remain patient compliance and antimicrobial resistance, and the promise shown by various patient education and compliance support platforms may help with this. Vonoprazan is, in many ways, the most exciting new drug to emerge for *H. pylori* eradication in a long time and further validation studies outside Asia are awaited with interest.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgments

None.

Informed Consent

Not Applicable.

Funding

None.

ORCID ID

0000-0003-1722-4820.

REFERENCES

1. Ledford H. The COVID pandemic's lingering impact on clinical trials. *Nature* 2021; 595: 341-342.
2. Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. *Gut Liver* 2021; 15: 168-195.
3. Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanás Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. *Rev Esp Enferm Dig* 2021; 113.

4. Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative effectiveness of multiple different first-line treatment regimens for *Helicobacter pylori* infection: A network meta-analysis. *Gastroenterology* 2021; 161: 495-507.
5. Zamani M, Alizadeh-Tabari S, Zamani V, Shokri-Shirvani J, Derakhshan MH. Worldwide and regional efficacy estimates of first-line *Helicobacter pylori* treatments: A systematic review and network meta-analysis. *J Clin Gastroenterol* 2022; 56: 114-124.
6. Shao QQ, Yu XC, Yu M, Ma J, Zhao JB, Yuan L, Qi YB, Hu RB, Wei PR, Xiao W, Lan L, Jia BL, Zhang LZ, Ding SZ. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for *Helicobacter pylori* eradication in central China: A single-center, prospective, open-label, randomized-controlled trial. *Helicobacter* 2022; 27: e12876.
7. Huang Q, Shi Z, Cheng H, Ye H, Zhang X. Efficacy and safety of modified dual therapy as the first-line regimen for the treatment of *Helicobacter pylori* infection: A meta-analysis of randomized controlled trials. *J Clin Gastroenterol* 2021; 55: 856-864.
8. Li C, Shi Y, Suo B, Tian X, Zhou L, Song Z. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the *Helicobacter pylori* eradication therapy within Asia: A systematic review and meta-analysis. *Helicobacter* 2021; 26: e12816.
9. Xu H, Wang W, Ma X, Feng R, Su Y, Cheng L, Yang Y, Zhang D. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for *H.pylori* infection: a network meta-analysis. *Eur J Gastroenterol Hepatol* 2021; 33: 775-786.
10. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, European Helicobacter and Microbiota Study Group and Consensus panel. Management of *Helicobacter pylori* infection - the Maastricht V/Florence Consensus Report. *Gut* 2017; 66: 6-30.
11. Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC; Taiwan Acid-related Disease, Microbiota (TARD-M) Consortium. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of *Helicobacter pylori* infection. *Helicobacter* 2021; 26: e12840.
12. He XJ, Zeng XP, Jiang CS, Liu G, Li DZ, Wang W. Efficacy and safety of antofloxacin-based triple therapy for *Helicobacter pylori* eradication failure in China. *Dig Dis Sci* 2022; 67: 208-215.
13. He XJ, Zeng XP, Jiang CS, Liu G, Li DZ, Wang W. Antofloxacin-based bismuth quadruple therapy is safe and effective in *Helicobacter pylori* eradication: A prospective, open-label, randomized trial. *Arab J Gastroenterol* 2021; 22: 47-51.
14. Yoon JY, Kwak MS, Jeon JW, Cha JM. Pretreatment with ranitidine bismuth citrate may improve success rates of *Helicobacter pylori* eradication: A prospective, randomized, controlled and open-label study. *Tohoku J Exp Med* 2021; 255: 41-48.
15. Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the *Helicobacter pylori* infection in Korea: a randomized open-label trial. *BMC Gastroenterol* 2021; 21: 95.
16. Wang J, Cao Y, He W, Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of *Helicobacter pylori*. *Medicine (Baltimore)* 2021; 100: e28323.
17. Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line *Helicobacter pylori* eradication: A systematic review and meta-analysis. *Microb Pathog* 2021; 152: 104661.
18. Cao Y, Zhang J, Liu Y, Zhang L, Wang L, Wang J, Qi Y, Lv H, Liu J, Huo L, Wei X, Shi Y. The efficacy and safety of different bismuth agents in *Helicobacter pylori* first-line eradication: A multicenter, randomized, controlled clinical trial. *Medicine (Baltimore)* 2021; 100: e27923.
19. Wang K, Lou D, Dai W, Fu R, Ma Z. Comparison of sequential therapy with concomitant therapy in first-line treatment of *Helicobacter pylori*: an updated meta-analysis. *J Med Microbiol* 2022; 71. doi: 10.1099/jmm.0.001490.
20. Hu Y, Ouyang Y, Zhu Y, Lu NH. Reverse hybrid therapy for *Helicobacter pylori* eradication: A systematic review and meta-analysis. *Helicobacter* 2021; 26: e12784.
21. Al-Ruthia Y, Almadi MA, Alqahtani S, Alrasheed H, Al-Owairdhi M, Alsohaibani F. The cost-effectiveness of sequential versus standard triple therapy for *Helicobacter pylori* eradication in Saudi Arabia. *Saudi J Gastroenterol* 2021; 27: 217-222.
22. Alhalabi M, Alassi MW, Alaa Eddin K, Cheha K. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for *Helicobacter pylori* infection: a prospective single-center randomized controlled trial. *BMC Infect Dis* 2021; 21: 642.
23. Gingold-Belfer R, Niv Y, Schmilovitz-Weiss H, Levi Z, Boltin D. Susceptibility-guided versus empirical treatment for *Helicobacter pylori* infection: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 2021; 36: 2649-2658.
24. Shah SC, Tepler A, Chung CP, Suarez G, Peek RM Jr, Hung A, Roumie C, Narula N. Host genetic determinants associated with *Helicobacter pylori* eradication treatment failure: A systematic review and meta-analysis. *Gastroenterology* 2021; 161: 1443-1459.
25. Fu J, Sun CF, He HY, Ojha SC, Shi H, Deng CL, Sheng YJ. The effect of CYP2C19 gene polymorphism on the eradication rate of *Helicobacter pylori* by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis. *Pharmacogenomics* 202; 22: 859-879.
26. Yang L, Zou A, Wu H, Guo H, Zhang F, Zou B, Wang J. Application of visual gene clip-based tailored therapy for the eradication of *Helicobacter pylori*. *Biomed Res Int* 2021; 2021: 6150628.

27. Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY. Cost-effectiveness of empirical bismuth-based quadruple therapy and tailored therapy after clarithromycin resistance tests for *Helicobacter pylori* eradication. *Dig Dis Sci* 2022; 67: 1222-1230.
28. Huang Y, Chen J, Ding Z, Liang X, Lu H. Susceptibility testing alone will not reliably achieve high *Helicobacter pylori* cure rates: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 2022; 37: 1212-1221.
29. Zha J, Li YY, Qu JY, Yang XX, Han ZX, Zuo X. Effects of enhanced education for patients with the *Helicobacter pylori* infection: A systematic review and meta-analysis. *Helicobacter* 2022; 27: e12880.
30. Ma H, Zhao XH, Zhang LL, Wu LM. Application of WeChat platform in the management of patients infected with *Helicobacter pylori*. *Helicobacter* 2021; 26: e12832.
31. Zhou BG, Yan XL, Wan LY, Zhang Q, Li B, Ai YW. Effect of enhanced patient instructions on *Helicobacter pylori* eradication: A systematic review and meta-analysis of randomized controlled trials. *Helicobacter* 2022; 27: e12869.
32. Chua BQY, Chong VWS, Teng TZJ, Chia CTW, Aung MO, Shelat VG. Does technology-enhanced communication improve *Helicobacter pylori* eradication outcomes?—A meta-analysis. *Helicobacter* 2022; 27: e12890.
33. Schubert JP, Gehlert J, Rayner CK, Roberts-Thomson IC, Costello S, Mangoni AA, Bryant RV. Antibiotic resistance of *Helicobacter pylori* in Australia and New Zealand: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 2021; 36: 1450-1456.
34. Hallur V, Panigrahi M, Sable M, Ghosh M, Mohanty S, Purkait S, Praharaj A. Low clarithromycin resistance in virulent *Helicobacter pylori* from dyspeptic patients at a tertiary care centre in Odisha. *Indian J Med Microbiol* 2022; 40: 211-216.
35. Tian L, Yao Y, Yin L, Wang L, An Z, Kang L, Ru C, Li J. Direct detection of antibiotic resistance in Chinese *Helicobacter pylori* clinical isolates by sequencing-based approach. *J Healthc Eng* 2022; 2022: 6436256.
36. Vanden Bulcke A, Waked B, Haems L, Lambrecht G, Hervent AS, Alliet G, Baert F, Vervaeke S. Antimicrobial resistance of *Helicobacter pylori* in West Flanders - Belgium: an observational cross-sectional study. *Acta Clin Belg* 2022; 77: 360-367.
37. Ho JJC, Navarro M, Sawyer K, Elfanagely Y, Moss SF. *Helicobacter pylori* antibiotic resistance in the United States between 2011-2021: A systematic review and meta-analysis. *Am J Gastroenterol* 2022 May 5. doi: 10.14309/ajg.0000000000001828. Online ahead of print.
38. Nestegard O, Moayeri B, Halvorsen FA, Tønnesen T, Sørbye SW, Paulssen E, Johnsen KM, Goll R, Florholmen JR, Melby KK. *Helicobacter pylori* resistance to antibiotics before and after treatment: Incidence of eradication failure. *PLoS One* 2022; 17: e0265322.
39. Azadbakht S, Moayyedkazemi A, Azadbakht S, Fard SA, Soroush S. Evaluation of antibiotic resistance of *Helicobacter pylori* bacteria obtained from gastric biopsy samples: A cohort study. *Ann Med Surg (Lond)* 2022; 78: 103824.
40. Li Y, Huang Z, Shang Y, Xie X, Yang R, Chen H, Wang Z, Xue L, Pang R, Zhang J, Ding Y, Chen M, Wang J, Chen J, Wu Q. Exploration of the molecular mechanisms underlying the antibiotic resistance of *Helicobacter pylori*: A whole-genome sequencing-based study in Southern China. *Helicobacter* 2022; 27: e12879.
41. Kouhsari E, Sadeghifard N, Khadiv A, Sayadi H, Amirani T, Ghafourian S, Valadbeigi H, Krutova M. Heteroresistance to clarithromycin and metronidazole in patients with a *Helicobacter pylori* infection: a systematic review and meta-analysis. *Ann Clin Microbiol Antimicrob* 2022; 21: 19.
42. Bunchorntavakul C, Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for *Helicobacter pylori*. *J Gastroenterol Hepatol* 2021; 36: 3308-3313.
43. Hu Y, Xu X, Ouyang YB, He C, Li NS, Xie C, Peng C, Zhu ZH, Xie Y, Shu X, Lu NH, Zhu Y. Optimization of vonoprazan-amoxicillin dual therapy for eradicating *Helicobacter pylori* infection in China: A prospective, randomized clinical pilot study. *Helicobacter* 2022; e12896.
44. Ghim JL, Chin MC, Jung J, Lee J, Kim S, Kim B, Song GS, Choi YK, Shin JG. Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects. *J Clin Pharmacol* 2021; 61: 913-922.
45. Kuang S, Xu J, Chen M, Zhang Y, Shi F, Lu X. The influence of pretreatment with PPI on *Helicobacter pylori* eradication: A systematic review and meta-analysis. *Medicine (Baltimore)* 2021; 100: e27944.
46. Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, Ji R, Wan M, Lin B, Lin M, Qi Q, Zuo X, Li Y. Clarithromycin versus furazolidone for naïve *Helicobacter pylori* infected patients in a high clarithromycin resistance area. *J Gastroenterol Hepatol* 2021; 36: 2383-2388.
47. Zhao J, Zou Y, Li K, Huang X, Niu C, Wang Z, Zhao S, Zhang Y, Song C, Xie Y. Doxycycline and minocycline in *Helicobacter pylori* treatment: A systematic review and meta-analysis. *Helicobacter* 2021; 26: e12839.
48. Gingold-Belfer R, Niv Y, Levi Z, Boltin D. Rifabutin triple therapy for first-line and rescue treatment of *Helicobacter pylori* infection: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 2021; 36: 1392-1402.
49. Yang C, Liang L, Lv P, Liu L, Wang S, Wang Z, Chen Y. Effects of non-viable *Lactobacillus reuteri* combining with 14-day standard triple therapy on *Helicobacter pylori* eradication: A randomized double-blind placebo-controlled trial. *Helicobacter* 2021; 26: e12856.
50. Chen MJ, Chen CC, Huang YC, Tseng CC, Hsu JT, Lin YF, Fang YJ, Wu MS, Liou JM; Taiwan Gastrointestinal Disease, *Helicobacter* Consortium. The efficacy of *Lactobacillus acidophilus* and *rhamnosus* in the reduction of bacterial load of *Helicobacter pylori* and modification of gut microbiota—a double-blind, placebo-controlled, randomized trial. *Helicobacter* 2021; 26: e12857.
51. Naghibzadeh N, Salmani F, Nomiri S, Tavakoli T. Investigating the effect of quadruple therapy with *Saccharomyces boulardii* or *Lactobacillus reuteri* strain (DSMZ 17648) supplements on eradication of *Helicobacter pylori* and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial. *BMC Gastroenterol* 2022; 22: 107.

52. Hablass FH, Lashen SA, Alsayed EA. Efficacy of lactoferrin with standard triple therapy or sequential therapy for *Helicobacter pylori* eradication: A randomized controlled trial. *Turk J Gastroenterol* 2021; 32: 742-749.
53. Viazis N, Argyriou K, Kotzampassi K, Christodoulou DK, Apostolopoulos P, Georgopoulos SD, Liatsos C, Giouleme O, Koustenis K, Veretanos C, Stogiannou D, Moutzoukis M, Poutakidis C, Mylonas II, Tseti I, Mantzaris GJ. A four-probiotics regimen combined with a standard *Helicobacter pylori*-eradication treatment reduces side effects and increases eradication rates. *Nutrients* 2022; 14: 632.
54. Cifuentes SG, Prado MB, Fornasini M, Cohen H, Baldeón ME, Cárdenas PA. *Saccharomyces boulardii* CNCM I-745 supplementation modifies the fecal resistome during *Helicobacter pylori* eradication therapy. *Helicobacter* 2022; 27: e12870.
55. El Shahawy MS, Shady ZM, Gaafar A. Influence of adding vitamin D3 to standard clarithromycin-based triple therapy on the eradication rates of *Helicobacter pylori* infection. *Arab J Gastroenterol* 2021; 22: 209-214.
56. Ozturk A. Periodontal treatment is associated with improvement in gastric *Helicobacter pylori* eradication: An updated meta-analysis of clinical trials. *Int Dent J* 2021; 71: 188-196.
57. Yuan Z, Xiao S, Li S, Suo B, Wang Y, Meng L, Liu Z, Yin Z, Xue Y, Zhou L. The impact of *Helicobacter pylori* infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. *Helicobacter* 2021; 26: e12848.
58. Guillemerd E, Poirel M, Schäfer F, Quinquis L, Rossoni C, Keicher C, Wagner F, Szajewska H, Barbut F, Derrien M, Malfertheiner P. A randomised, controlled trial: Effect of a multi-strain fermented milk on the gut microbiota recovery after *Helicobacter pylori* therapy. *Nutrients* 2021; 13: 3171.
59. Guo Y, Cao XS, Guo GY, Zhou MG, Yu B. Effect of *Helicobacter pylori* eradication on human gastric microbiota: A systematic review and meta-analysis. *Front Cell Infect Microbiol* 2022; 12: 899248.
60. Song X, Cai C, Jin Q, Chen X, Yu C. The efficacy of *Helicobacter pylori* eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis. *Helicobacter* 2021; 26: e12781.
61. Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of *Helicobacter pylori*. *Helicobacter* 2022; 27: e12860.
62. Zhao H, Yan P, Zhang N, Feng L, Chu X, Cui G, Qin Y, Yang C, Wang S, Yang K. The recurrence rate of *Helicobacter pylori* in recent 10 years: A systematic review and meta-analysis. *Helicobacter* 2021; 26: e12852.
63. Zhao JB, Yuan L, Yu XC, Shao QQ, Ma J, Yu M, Wu Y, Qi YB, Hu RB, Wei PR, Jia BL, Zhang LZ, Zhang YR, Ding SZ. Whole family-based *Helicobacter pylori* eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis. *Helicobacter* 2021; 26: e12793.
64. Song Z, Chen Y, Lu H, Zeng Z, Wang W, Liu X, Zhang G, Du Q, Xia X, Li C, Jiang S, Wu T, Li P, He S, Zhu Y, Zhang G, Xu J, Li Y, Huo L, Lan C, Miao Y, Jiang H, Chen P, Shi L, Tuo B, Zhang D, Jiang K, Wang J, Yao P, Huang X, Yang S, Wang X, Zhou L. Diagnosis and treatment of *Helicobacter pylori* infection by physicians in China: A nationwide cross-sectional study. *Helicobacter* 2022; 27: e12889.
65. Graham DY, Hernaez R, Rokkas T. Cross-roads for meta-analysis and network meta-analysis of *H. pylori* therapy. *Gut* 2022; 71: 643-650.